Cytokine-Secreting based Next-Generation TIL Development Service

Online Inquiry

Cytokine-Secreting Next-Generation TIL Development: A Promising Approach in Cancer Immunotherapy

Tumor-infiltrating lymphocytes (TILs) are immune cells that infiltrate solid tumors and hold significant promise as a powerful tool in cancer immunotherapy. Despite their potential, the clinical efficacy of TIL therapy is currently limited to a subset of patients. To enhance their therapeutic potential, researchers are exploring innovative strategies, including genetic engineering to equip TILs with cytokine-secreting capabilities. This approach has demonstrated the potential to prolong TIL survival, improve tumor recognition and eradication, and ultimately lead to the development of more effective and widely applicable TIL-based immunotherapies.

Fig.1 Crosstalk of B cells with other immune cells in the tumor microenvironment. Fig.1 B lymphocytes communicate with other immune cells in the tumor microenvironment.¹

Cytokine-Secreting based Next-generation TIL Development Service at Creative Biolabs

Creative Biolabs offers an integrated cytokine-secreting based next-generation TIL development service to advance the development of next-generation TIL therapies. By engineering TILs to secrete specific cytokines, we aim to enhance their anti-tumor activity and overcome limitations associated with traditional TIL therapies.

Our comprehensive services encompass TIL isolation and expansion from patient tumor biopsies, selection and genetic engineering of TILs with optimal cytokines for specific tumor types using advanced techniques, and rigorous functional characterization to assess cytokine secretion profiles, cytotoxicity, proliferation, and anti-tumor activity in preclinical models. Throughout the whole process, we provide multiple development strategies to design for your projects, including selective engineering approaches, diverse cytokine engineering, and adaptable cytokine release formats. If you have a specific demand, our scientists also have the ability to customize your desired experiment plans. Furthermore, our operations adhere to industry regulatory requirements and are outfitted with a range of cutting-edge technology to guarantee that the results delivered to our customers are high-quality and trustworthy.

Fig.2 Service process. (Creative Biolabs Original) Fig.2 The cytokine-secreting based next-generation TIL development process.

Selective Engineering Strategies

Gene editing offers a powerful approach to enhance the therapeutic potential of tumor-infiltrating lymphocytes (TILs) by improving their survival, resistance to immunosuppression, and tumor eradication ability. We provide various gene editing strategies to empower our customers' projects, enabling the development of cutting-edge TIL-based immunotherapies.

Viral Vectors: Retroviruses and lentiviruses are commonly used to introduce cytokine genes into TILs.
Non-Viral Approaches: Alternative techniques for gene transfer include electroporation and lipid-based transfection.

Multiple Available Cytokine Types

Here are some available validated cytokines that can be engineered directly. Importantly, we are also able to customize details to satisfy your requirements.

Pro-inflammatory Cytokines: TNF-α, IL-2, and IFN-γ may improve the cytotoxicity and proliferation of TILs.
Immunomodulatory Cytokines: IL-12 and IL-15 can stimulate a robust anti-tumor immune response.

Controlled Cytokine Release

Controlled cytokine release is a crucial strategy in next-generation TIL development as it offers several significant advantages such as enhanced anti-tumor efficacy, reduced systemic toxicity, improved TIL persistence, etc. The following we deliver several references to enable your TIL projects more efficient.

Inducible Promoters: The promoters enable targeted cytokine production in response to specific stimuli, such as tumor antigens or other variables.
Biodegradable Carriers: Encapsulating cytokine-secreting TILs in biodegradable materials can provide sustained release of cytokines.

Our Service Advantages

Wealthy of Expertise and Experience
Advanced Technologies
Customized Solutions
Regulatory Compliance

Frequently Asked Question

Q1: How do you ensure the safety and efficacy of cytokine-secreting TILs?

A1: Creative Biolabs follows rigorous quality control standards and conducts extensive preclinical studies to assess the safety and efficacy of cytokine-secreting TILs. We follow regulatory guidelines to guarantee the safety of delivered products.

Reference

Zhang, Enkui, et al. "Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy." Biomarker Research 11.1 (2023): 28. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.